Characterization of the novel KIR3DL2 allele, KIR3DL2*113.

KIR3DL2 novel allele polymerase chain reaction sequence-based typing

Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
06 2020
Historique:
received: 19 01 2020
revised: 27 01 2020
accepted: 01 02 2020
pubmed: 7 2 2020
medline: 22 6 2021
entrez: 7 2 2020
Statut: ppublish

Résumé

The new allele KIR3DL2*113 showed one nucleotide difference with KIR3DL2*0020101 at codon 345.

Identifiants

pubmed: 32026627
doi: 10.1111/tan.13821
doi:

Substances chimiques

KIR3DL2 protein, human 0
Receptors, KIR3DL2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

594-596

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Gwozdowicz S, Nestorowicz K, Graczyk-Pol E, et al. KIR specificity and avidity of standard and unusual C1, C2, Bw4, Bw6 and A3/11 amino acid motifs at entire HLA:KIR interface between NK and target cells, the functional and evolutionary classification of HLA class I molecules. Int J Immunogenet. 2019;46(4):217-231.
Weisdorf D, Cooley S, Wang T, et al. KIR donor selection: feasibility in identifying better donors. Biol Blood Marrow Transplant. 2019;25(1):e28-e32.
Torío A, Pascual MJ, Vidales I, Ortiz M, Caballero A, Heiniger AI. Donor selection based on killer cell immunoglobulin-like receptor (KIR) genotype may improve outcome after T-cell-replete Haploidentical transplantation. Transplant Proc. 2018;50(2):679-682.
Augusto DG, Petzl-Erler ML. KIR and HLA under pressure: evidences of coevolution across worldwide populations. Hum Genet. 2015;134(9):929-940.
Marsh SGE, Parham P, Dupont B, et al. Killer-cell immunoglobulin-like receptor (KIR) Nomenclature Report, 2002. Tissue Antigens. 2003;62(1):79-86.

Auteurs

Chen Chen (C)

HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.
Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China.

Jielin Wang (J)

HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.
Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China.

Gang Xu (G)

HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.
Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China.

Ji He (J)

HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.
Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China.

Faming Zhu (F)

HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.
Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH